FDA-approved integrase strand transfer inhibitors (raltegravir, elvitegravir and dolutegravir) efficiently inhibit HIV-1 replication. Here, we present fluorescence properties of these inhibitors. Dolutegravir displays an excitation mode particularly dependent on Mg 2+ chelation, allowing to directly probe its Mg 2+ -dependent binding to the prototype foamy virus (PFV) integrase. Dolutegravir-binding studied by both its fluorescence anisotropy and subsequent emission enhancement, strictly requires a preformed integrase/DNA complex, the ten terminal base pairs from the 3′-end of the DNA reactive strand being crucial to optimize dolutegravir-binding in the context of the ternary complex. From the protein side, mutation of any catalytic residue fully abolishes dolutegravir-binding. We also compared dolutegravir-binding to PFV F190Y, G187R and S217K mutants, corresponding to HIV-1 F121Y, G118R and G140S/Q148K mutations that confer low-to-high resistance levels against raltegravir/ dolutegravir. The dolutegravir-binding properties derived from fluorescence-based binding assays and drug susceptibilities in terms of catalytic activity, are well correlated. Indeed, dolutegravir-binding to wild-type and F190Y integrases are comparable while strongly compromised with G187R and S217K. Accordingly, the two latter mutants are highly resistant to dolutegravir while F190Y shows only moderate or no resistance. Intrinsic fluorescence properties of dolutegravir are thus particularly suitable for a thorough characterization of both DNA-binding properties of integrase and resistance mutations.
Integration of the HIV-1 genome into the host genome is a crucial event in the retrovirus life cycle and corresponds to a two-step reaction catalysed by integrase (IN) [1] [2] [3] . The first step corresponds to the 3′-processing reaction (3′P) that involves cleavage of the 3′-terminal dinucleotide at each viral DNA end. The hydroxyl groups of newly recessed 3′-ends are used in the second step, named strand transfer (ST) for the covalent joining of viral and target DNAs, resulting in full-site integration.
IN strand transfer inhibitors (INSTIs) [3] [4] [5] [6] , together with allosteric inhibitors of IN [7] [8] [9] [10] [11] [12] [13] , efficiently inhibit viral replication. Allosteric inhibitors correspond to noncatalytic site inhibitors of IN and may interfere with distinct steps than integration, whereas INSTIs target the active site of IN and consistently inhibit the overall integration process by specifically blocking the ST reaction. To date, only INSTI compounds have been developed for use in patients. Among them, Raltegravir (RAL) and elvitegravir (EVG) (first generation of IN inhibitors) as well as dolutegravir (DTG) (second generation) are three potent INSTIs approved by the US FDA [14] [15] [16] [17] [18] . Regarding RAL-resistance mutations, three resistance pathways have been identified, involving primary mutations at positions Y143, Q148 and N155 in the HIV-1 IN (IN  HIV ) sequence [19] [20] [21] . If EVG displays extensive cross-resistance with RAL, the second-generation DTG compound which is intrinsically more potent against IN, leads to efficient inhibition of N155 and Y143 pathways, albeit some resistance to DTG may be associated with the Q148 pathway [22] [23] [24] . To date, there is no specific resistance pathway identified in DTG-treated patients. Recently, we have identified and characterized two novel single mutations, G118R and F121Y, originally described in patients failing RAL-containing regimens, that also confer resistance against DTG, however, to different extents (G118R»F121Y) 24 . , and several structures exist in the presence of INSTI such as RAL and EVG 26, 28 as well as with second-generation DTG and MK2048 inhibitors 28, 29 . The structure of a PFV intasome/nucleosome complex at 7.8 Å-resolution obtained by cryo-electron microscopy is also available 30 . IN PFV structure is a valuable model for investigating many properties of IN HIV , including catalytic mechanism of integration, IN-DNA interactions (with both donor and target DNAs) as well as interactions with INSTIs. In the latter case, IN PVF -inhibitor complexes may provide platforms for structure-based design of new inhibitors with reduced susceptibilities to resistance mutations 31 .
Laboratory of Biology and
Here, we present fluorescence properties of RAL, EVG and DTG. Among them, DTG particularly displays interesting fluorescence emission characteristics. Although DTG alone in aqueous solution was poorly fluorescent per se, a significant fluorescence enhancement was specifically observed upon complexation with Mg 2+ . This is relevant in the context of IN since (i) Mg 2+ as a metallic divalent cation represents the physiological cofactor for IN activity and a pair of metal cations is visible in the active site of published structures, coordinated to the catalytic triad motif (DD35E) between the side chains of D128/D185 and D128/E221, respectively 26, 28 , (ii) in addition to drug/amino-acid interactions, three co-planar atoms (mainly oxygen) of INSTIs are coordinated to both metal ions in the active site, the central oxygen being coordinated to both ions 26, 28, 29 and define the metal-coordinating concentrations. EVG and DTG were studied in buffer A whereas RAL was studied in buffer A-10% EtOH (v/v). Corresponding excitation and emission spectra are shown in Supplementary Fig. S1 . Excitation and emission slits: Δλ ex = Δλ em = 5 nm (PMT = 750 V). The fluorescence enhancement factor corresponds to the drug fluorescence emission intensity for a given Mg 2+ concentration normalized by the intensity in the absence of Mg Supplementary Fig. S1 ). The wavelengths of maximum emission intensity were 405, 395 and 354 nm, for RAL, DTG and EVG, respectively. Significant blue-shifts of one excitation mode of RAL (320→300 nm) and its emission wavelength (405→363 nm) with a net increase in the fluorescence intensity was observed in the presence of ethanol only (buffer A-EtOH 10% (v/v)) ( Supplementary Fig. S1 ). However, RAL was characterized by a very low fluorescence emission, regardless of Mg 2+ concentration (Fig. 1A) . By contrast, EVG and DTG were intrinsically more fluorescent in buffer A and excitation at 262/265 nm led to higher fluorescence than excitation at 314/345 nm (Fig. 1A) . Furthermore, both drugs display a Mg 2+ dependence of fluorescence intensity, however with some differences. A slight increase of EVG fluorescence intensity was observed upon addition of Mg 2+ (a 3-fold increase for the two excitation modes from 0 to 10 mM Mg 2+ ; Fig. 1B ). DTG fluorescence emission was more Mg 2+ -dependent than EVG with, interestingly, the second excitation mode (345 nm) leading to a stronger Mg 2+ dependence of emission intensity than the first one (265 nm) (a 27-30-fold and a 8-10-fold increase at 345 and 265 nm, respectively, from 0 to 10 mM Mg 2+ ; Fig. 1B (Fig. 1D ). This Mg 2+ -dependent enhancement is related to an increase of the fluorescence quantum yield since no Mg 2+ -dependent change in the absorption spectrum was observed ( Supplementary Fig. S2A ). Moreover, the increase of medium viscosity mimics the Mg 2+ effect in terms of fluorescence enhancement ( Supplementary  Fig. S2B ): only EVG and DTG displayed a glycerol-dependent fluorescence enhancement, showing that molecular geometry (planarity) and internal dynamics accounts for the quantum yield increase, although the particularly high fluorescence enhancement of DTG in the 345nm-excitation mode appears to be specific of Mg 2+ chelation. This large Mg 2+ -dependent enhancement of DTG fluorescence intensity upon excitation at 345 nm was used in the following sections to directly probe drug binding to IN since (i) Mg 2+ is the physiologically relevant catalytic cofactor coordinated in the protein active site and (ii) INSTI binding to the active site is dependent on Mg 37 . The quantification of DTG bound to the binary complex, based on fluorescence enhancement, was determined either by varying the concentration of binary complexes (for a given DTG concentration) or by varying DTG concentration (for a given concentration of binary complexes). Results were consistent and led to K d values in the sub-to-low micromolar range (0.4-1.4 μM) for the ternary DTG-IN-DNA complex (Fig. 3) .
Although the measurement of DTG fluorescence enhancement should account for binding events of DTG to Mg 2+ -IN-DNA complexes only, we checked that binding properties of DTG as measured by its intrinsic fluorescence, were not strongly influenced by the Mg 2+ concentration of the sample. This is an important issue since 10 mM Mg 2+ is optimal for IN activity whereas 1 mM Mg 2+ corresponds to a sub-optimal condition ( Supplementary Fig. S3) . Similar experiments were then conducted using 10 mM Mg 2+ . As expected (see above), no significant DTG fluorescence emission enhancement was observed upon addition of IN-PVF CAAT complexes, in contrast to results obtained with 1 mM Mg 2+ , although the blue-shift of the maximum emission wavelength was consistently observed (Supplementary Fig. S4A ) accounting for a modest but significant increase in the DTG fluorescence intensity in the 375-385 nm region with 10 mM Mg 2+ (see also Fig. 2B ). Altogether, our results indicate that the proper Mg 2+ complexation effect accounts for DTG emission intensity enhancement whereas the concomitant binding to the IN active site accounts for a classical emission wavelength blue-shift for polarity reasons 38 . This net increase, although modest compared to the 1 mM Mg 2+ condition (resulting in titration curves of smaller amplitude; Supplementary Fig. S4A, inset) , allowed an estimation of the K d value for the ternary complex (≈0.7 μM) ( Supplementary Fig. S4B -C) which is consistent with the value found in the presence of 1 mM Mg 2+ . However, if the fluorescence intensity appears to be suitable for measuring the formation of ternary complexes in the presence of 1 mM Mg 2+ , it appears suboptimal using 10 mM due to the lower amplitude of the enhancement process.
Alternatively, to overcome this difficulty, we measured the steady-state fluorescence anisotropy (r) of DTG itself in the presence of increasing concentrations of binary IN-PVF CAAT complexes and 10 mM Mg 2+ . The rotational mobility of the drug should be constrained upon binding to its target. As shown in Fig. 4A , the r value continuously increased as a function of (IN + PFV CAAT ), leading to a K d value of 1.0 ± 0.15 μM characterizing the ternary complex (Fig. 4B ). This value is consistent with the value determined either by fluorescence anisotropy with 1 mM Mg 2+ ( Fig. 4C-F) or by fluorescence intensity, regardless of Mg 2+ concentration. Altogether, our results show that both DTG fluorescence intensity and anisotropy are suitable for the study of the interaction between DTG and the binary IN-DNA complex using 1 mM Mg 2+ whereas mainly anisotropy is suitable using 10 mM Mg Table 1 ) was compared to other complexes obtained with 21-bp DNAs containing varying lengths of the cognate PFV sequence from the reactive strand 3′-end (for example: 16-bp in the case of DNA#2, 4-bp in the case of DNA#8; Table 1 ); DNA#9 corresponds to a non-specific (random) sequence. DTG binding to the different binary complexes was then measured using the fluorescence intensity procedure or the r parameter (columns 3 & 4; Table 1 ). DTG displayed good and similar binding activities to IN in complex with DNA#2→6 (>76% of the binding activity obtained with DNA#1) while a significantly lower binding activity was observed with DNA#7→9, suggesting that the 10 terminal base-pairs from the reactive strand 3′-end were sufficient to ensure DTG binding to the binary complex. Among these 10 positions, at least pos. 10 and the CA sequence (pos 3-4 preceding the 3′P cleavage site) are strictly required. Indeed, DTG binding to the binary complex was low using DNA#10 (CAAT-3′→AGGT-3′) and DNA#11 (CAAT-3′→AGAT-3′). By contrast, DTG binding was higher with DNA#12 (CAAT-3′→CAGT-3′) (72-77% of the binding activity obtained with DNA#1). This indicates that the nature of nucleotides at pos. 1/2 on both DNA strands is not crucial for DTG binding. Consistent with this observation, the pre-processed DNA substrate (DNA#13) led to efficient DTG binding which is expected since INSTIs that do not prevent 3′P, strongly inhibit the ST reaction 5 . To note, structural studies suggest an even higher stability or selectivity of the INSTI in the active site occupied by the processed DNA 39 . Such a situation is not observed in the present study since DTG binding in the DNA#13 context (processed LTR end) remains slightly lower compared to the DNA#1 context (blunt LTR end), in agreement with the lower ST inhibition efficiency of INSTI observed when using the pre-processed compared to the blunt substrate 40 . Moreover, INSTI such as RAL was shown to tightly bind to both processed and blunt LTR ends 41 . Altogether, results by us and others suggest that the active site may accommodate INSTI and blunt LTR end (i.e. LTR processing is not strictly required for INSTI binding) in a manner that not or minimally affects 3′P 42 . The apparent discrepancy with structure-based considerations could originate from the molecular nature of the complex considered, with the synaptic complex competent for the full-site integration reaction 39 characterized by a higher selectivity toward the processed LTR end than the complex competent for the half-site ST reaction (present study and 40 ). The results in Table 1 cannot discriminate between a direct sequence effect on DTG-binding from an indirect effect via a possible defect in the IN-DNA interaction. The binding of IN to various DNA sequences (DNA#1 #8 #9 and #13) was similar, as measured by fluorescence anisotropy using fluorescein-labeled DNAs ( Supplementary  Fig. S5A ). However, we cannot rule out from the anisotropy assay, which quantifies the overall amount of IN-DNA complexes in the sample without any information regarding the positioning of IN onto DNA, that some sequence-dependent subtle changes in the specific interactions between IN and DNA may occur and thus indirectly perturb DTG binding. The X-ray structure of the IN PFV -DNA complex highlights specific contacts (about 9) between amino acids and the bases of the two strands (i.e. reactive and non-transferred DNA strands), up to the 10 th position from the reactive strand 3′-end 26 . In particular, there is a specific contact involving a guanine of the non-transferred strand at pos. 10 and the N69 residue. A modification of this base could perturb the positioning of IN onto DNA and, then indirectly prevent DTG binding (compare DNA#6 and #7; Table 1 ). Indeed, the significantly reduced ST activity using substrate DNA#7 (compared with the slight decrease observed with DNA#6; Supplementary Fig. S5B ), combined to the absence of ST inhibition by DTG using IN-DNA#7 complexes while IN-DNA#1 and IN-DNA#6 complexes remained DTG-sensitive ( Supplementary Fig. S5C ), highlight a . The percentages of ternary complexes (or % of bound DTG) were derived from the plots shown in panels A & C, respectively: % = (r − r 0 )/[(r max − r)(I max /I 0 ) + (r − r 0 )] × 100 where r 0 and r max correspond to anisotropy values of free and bound DTG, respectively; I 0 and I max correspond to intensities of free and bound DTG, respectively (to account for the change in DTG intensity; see insets in panels A and C). The binary complex concentration was measured as explained in Fig. 2E . (E) Fluorescence intensity of a 0.6μM-DTG solution (integrated in the 375-385 nm spectral region) as a function of (IN + DNA). λ ex = 345 nm and PMT = 980 V (Δλ ex = Δλ em = 5 nm). The DTG emission enhancement was used for the calculation of the percentage of ternary complexes (as explained in the legend of Fig. 2C-D) . This percentage was then plotted against the concentration of the binary complex (F). The titration curve led to a K d value of 0.7 ± 0.25 μM which is consistent with both (i) the value obtained with 0.3 μM DTG using the same approach (fluorescence enhancement): K d = 0.4 ± 0.1 μM (Fig. 3A) and (ii) the value obtained with 0.6 μM DTG using the anisotropybased approach: K d = 0.5 ± 0.15 μM (panel D). All graphs show representative data of three (panels A and B) or two (panels C-F) independent experiments.
Scientific REPORTS | 7: 14067 | DOI:10.1038/s41598-017-14564-w correlation between the capability of the binary IN-DNA complex to bind DTG and its catalytic property. This suggests that DTG binding requires a precise positioning of IN onto DNA ( = catalytically active complex). To note, based on X-ray structures of ternary RAL/or DTG-IN-DNA complexes 26, 29 in which the INSTI has direct contacts with several bases at pos. 3 and 4 (A3 and C4 on the reactive strand and G4 on the non-transferred strand) with an even closer contact between G4 and the DTG halogenated phenyl group 29 , the influence of these two positions could be more related to specific drug-DNA contacts.
Monitoring the DTG-binding process to various IN mutants. Recently, we have characterized two new single mutations involving G118 and F121 residues in IN
HIV that confer resistance against RAL and DTG, albeit to different extents (G118R being more resistant than F121Y) 24 . DTG binding to analogous G187R and F190Y IN PFV was then investigated using fluorescence-based DTG-binding assays and compared to results obtained with the S217K IN PFV mutant (equivalent to the RAL/DTG resistant G140S/Q148K IN HIV double mutant 24 . No binding of DTG to G187R or S217K was observed whereas a slight but significant decrease of the plateau value was observed with F190Y (Fig. 5A) . These results indicate dramatic effects of G→R and S→K mutations at pos. 187 and 217, respectively, on the ternary DTG-IN-DNA complex formation whereas we cannot exclude in the latter case an influence of the F→Y mutation on DTG emission in terms of polarity change, compatible with the close proximity of DTG and the phenyl ring of residue 190 29 . Consistent with this hypothesis, normalized DTG-binding curves were similar for the wt IN and F190Y indicating that the F→Y mutation did not directly and strongly influence DTG binding, in contrast to that observed with G187R or S217K (Fig. 5B) . To note, the DTG-binding impairment, as observed for the G187R or S217K mutant, was not related to a net decrease of the total amount of IN-DNA complexes (Supplementary Fig. S6 ). We found that proteins susceptibility to DTG in the ST activity assay closely paralleled DTG-binding properties directly probed by the fluorescence-based DTG-binding assay (Fig. 6 ). S217K and G187R displayed highly resistant profiles (IC 50 = 500 nM and >1 μM, respectively) while the wt IN PFV and the F190Y mutant were similarly inhibited with IC 50 values in the 5-15 nM range.
The DTG-binding defects of G187R and S217K mutants are apparently comparable to those observed for the three catalytic triad mutants (D128N, D185N and E221A corresponding to HIV-1 D64N, D116N and E152A, respectively) ( Fig. 5A-B) . Taking into account that Mg 2+ concentration is suboptimal in the fluorescence intensity-based assay (1 mM), the measurement of DTG-binding was repeated in the presence of 10 mM Mg 2+ by monitoring DTG anisotropy as described above: the DTG-binding defects of G187R and S217K were consistently observed in this condition (Fig. 5C) (Supplementary Fig. S6 ). However, G187R cannot be considered as a catalytic mutant since it sustains a significant ST activity although weak (≈10% of the wt activity; Fig. 6 ). In the case of S217K, the ST activity was significantly higher (≈60% of the wt activity; Fig. 6 ).
Interestingly, X-ray structures of S217Q/H mutants show a loss of metal binding suggesting that the presence of a bulky side chain could be responsible for a reduction in cofactor binding affinity due a displacement of the D185 residue 28 . However, authors exclude that this could be a direct explanation for the decreased INSTI susceptibility of S217H because S217Q and wt IN PFV displays similar INST susceptibilities; they show that S217H requires a larger backbone conformational change in the active site, representing a higher energy cost to accommodate the 2 nd -generation inhibitor MK2048 compared with S217Q 28 . Taking into account that (i) DTG and MK2048 share similar binding modes in the IN active site 29 and (ii) the decrease in DTG susceptibility is significantly higher for S217K than S217H (≈50-fold and 2-3-fold, respectively) (Fig. 6) 29 , we can reasonably assume a common mechanism of resistance for S217K/H mutants with a steric hindrance effect which is even more accentuated in the case of the S→K substitution, explaining the dramatic DTG-binding defect of the S217K mutant. Based on the strongly reduced activity of G187R compared to the wt IN or S217K, we cannot totally exclude a problem of Mg 2+ chelation for G187R that could be indirectly responsible for the DTG-binding defect. Not mutually exclusive with such an indirect effect of the G→R mutation, a direct effect (i.e. loss of an IN-drug contact) is also likely to be involved, consistent with X-ray structures of ternary drug-IN-DNA complexes showing that DTG as well as MK2048 extend toward the G187 residue via the tricyclic metal-chelating cores 29 .
In conclusion, the Mg 2+ -dependent DTG fluorescence emission allowed the development of two fluorescence-based assays to directly probe DTG binding to the binary IN-DNA complex. The first one is based on the fluorescence enhancement/blue shifted emission of the drug upon Mg 2+ complexation and requires suboptimal (relative to IN activity) Mg 2+ concentrations (e.g. 1 mM). The second one is based on the measurement of DTG fluorescence anisotropy that significantly increases upon its binding to the binary complex. In contrast to the first approach, the anisotropy-based approach is not limited by Mg 2+ concentration and is compatible with optimal Mg 2+ concentrations for IN activity (e.g. 10 mM). However, due to the use of polarizers that inherently diminishes detection sensitivity, the second approach requires higher DTG concentrations than the first one (typically 0.6 vs 0.3 μM). Nevertheless, the two approaches are consistent with each other, although not really surprising since only DTG in the context of Mg Fig. S7 ). Moreover, the intrinsic ability of INSTI to also inhibit 3′P activity has been recently described but this occurs only above micromolar drug concentrations 49, 50 . All considerations mentioned above explain why the fluorescence-based DTG-binding assay remains robust and (Table 1 ) and increasing concentrations of DTG. ST products were quantified as explained in the Methods section. The effect of DTG on the DNA-binding properties of IN is shown in Supplementary Fig. S7 .
predictive of both DNA-binding properties and resistance mutations of IN and could be extended to the study of other resistance mutations against DTG or EVG, the anisotropy mode being more suitable in the latter case since EVG fluorescence emission is not strongly dependent on Mg 2+ chelation.
Methods
Oligonucleotides for DTG-and DNA-binding assays, INSTI compounds. Unlabeled and fluorescein(Fl)-labeled DNAs were purchased from Eurogentec (Belgium) and further purified on polyacrylamide gel 25 . Sequences and names of DNAs are reported in Table 1 . Dolutegravir, raltegravir and elvitegravir were generous gifts from Pr. Vincent Calvez (Hopital Pitié-Salpêtrière, Paris).
Site-directed mutagenesis and purification of IN
PFV mutants. IN PFV mutants (D128N, D185N, E221A, G187R, F190Y and S217K) were constructed using the QuikChange Lightning site-directed mutagenesis kit (Agilent) according to manufacturer's instructions. The pET-IN-PFV plasmid containing the full-length IN gene was used for mutagenesis 25 . Nucleotide sequences of mutagenic primers are explicitly shown in Supplementary Table S1 . The resulting plasmids were prepared after transformation of E. coli XL10-Gold ultracompetent cells (Agilent) (cells were grown in LB medium containing 100 μg/ml ampicillin at 37 °C) using the QIAprep Spin Miniprep kit (Quiagen) and were sequenced (Eurofins Genomics) across the entire IN-encoding region to ensure that no unintended nucleotide change was introduced during the mutagenesis procedure.
The full-length wt IN PFV , the three single mutants of the catalytic triad (D128N, D185N, E221A) and RAL/ DTG-resistant mutants (G187R, F190Y, S217K) were expressed using E. coli BL21-CodonPlus (DE3)-RIPL cells (Agilent) (cells were grown in LB medium containing 100 μg/ml ampicillin at 37 °C) and purified under native conditions. The purification was based on a batch procedure by using Ni-NTA agarose beads (Qiagen). At an OD (600 nm) of 0.6-0.8, His-tagged PFV IN expression was induced in bacterial cultures by the addition of IPTG (1 mM) and cultured for additional 4 h at 37 °C. Cells were harvested by centrifugation and frozen at −20 °C. Cells from 1 liter culture were resuspended in 24 ml of ice-cold filtered purification buffer (20 mM Tris-HCl pH 8, 1 M NaCl, 4 mM β-mercaptoethanol) supplemented with 5 mM imidazole (Im) and EDTA-free Protease Inhibitor Cocktail (Roche)). Cells were lysed in a French press and centrifuged (30 min at 10,000 rpm). The supernatant was filtered (0.45μm pore size) and incubated overnight with Ni-NTA agarose beads (Qiagen). The beads were washed twice with 10 vol. of purification buffer + 5 mM Im, 10 vol. of purification buffer + 50 mM Im, and 10 vol. of purification buffer + 100 mM Im. IN was then eluted with purification buffer supplemented with 50 μM ZnSO 4 and 1 M Im. Im was removed by overnight dialysis against purification buffer supplemented with 50 μM ZnSO 4 and 10% ethylene glycol (v/v). Fractions were aliquoted and frozen at −80 °C.
Characterizations of IN
PFV ST activity and susceptibility to DTG. DNA#13 mimicking the 3′-processed end (Table 1) were analyzed with a Typhoon TRIO variable mode imager (GE Healthcare) and quantified with ImageQuant TL software. ST activity was expressed as the % of the signal intensity of ST products divided by the signal intensity of the DNA substrate. DTG susceptibilities of wt IN and mutants were determined by measuring ST activity in the presence of increasing drug concentrations. IC 50 values were determined using the Prism 5.0 software. IN-drug or (IN-DNA) -drug interactions by steady-state fluorescence intensity and anisotropy. Fluorescence excitation and emission spectra of INSTIs were recorded on a Eclipse (Varian) spectrofluorimeter equipped with two polarizers for anisotropy measurements and a thermostated cell holder, using 80 µl solutions placed in micro cells (Hellma). Drug, IN and DNA concentrations, excitation/emission slit settings as well as the photomultiplier tube (PMT) voltage are specified in figure legends. The intensity value was corrected from the inner filter effect. The steady-state fluorescence anisotropy was calculated using: r = (I VV -G x I VH )/(I VV + 2GxI VH ) where I VV and I VH correspond to vertical and horizontal components, respectively, when the sample is excited with vertically polarized light. G represents the correction factor for the difference in the monochromator transmission between // and ⊥ polarized components: G = I HV /I HH . All experiments were performed at 25 °C in buffer A: 20 mM Tris pH 7.2, 50 mM NaCl, 1 mM DTT and 10% (v/v) DMSO.
Measurements of

Measurement of the IN-DNA interaction by steady-state fluorescence anisotropy. IN
PFV binding to DNA was measured by fluorescence anisotropy on a Beacon Instrument (Panvera, Madison, WI, USA) as previously described 25, 51 , using a double-stranded 21-mer Fl-labeled DNA mimicking the PFV U5 LTR end also referred to as DNA#1 in Table 1 (labeled at the 5′-end of the reactive strand). IN binding to Fl-PFV CAAT (or Fl-DNA#1) was compared to the binding to other DNA sequences (Fl-DNA#8 #9 #13). DNA annealing was obtained by mixing equimolar amounts of complementary strands in buffer A, heating to 85 °C for 5 min and slow cooling to 25 °C. DNA-binding experiments were performed at 25 °C in buffer A.
Statistical analysis. Statistical significance was determined using the paired t-test and two-way ANOVA (GraphPad Prism 5).
